A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Seletalisib (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors UCB
- 04 Jan 2018 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2017 This trial has been Discontinued in Spain according to European Clinical Trials Database record.
- 07 Nov 2017 Planned End Date changed from 1 Jul 2018 to 1 Nov 2017.